Age: 27.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19
Clinical narrative: COVID-19; This spontaneous case was reported by an other health care professional and describes the occurrence of COVID-19 (COVID-19) in a 27-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 034F21A, 010M20A and 013L20A) for COVID-19 vaccination.     Concurrent medical conditions included Asthma, Endometriosis, Latex allergy, Drug allergy (Bactrim) and Drug allergy (flagyl). Concomitant products included PROPRANOLOL (PROPANOLOL [PROPRANOLOL]), CETIRIZINE HYDROCHLORIDE (ZYRTEC [CETIRIZINE HYDROCHLORIDE]), ETHINYLESTRADIOL, NORGESTIMATE (SPRINTEC), FLUOXETINE and HYDROXYZINE for an unknown indication.   On 19-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 16-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 26-Nov-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced COVID-19 (COVID-19). The patient was treated with NIRMATRELVIR, RITONAVIR (PAXLOVID) from 26-May-2022 to 31-May-2022 for COVID-19 treatment, at an unspecified dose and frequency. At the time of the report, COVID-19 (COVID-19) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   COVID rebound occurred 2 days after finishing Paxlovid, on 03-Jun-2022 which was not recovered. Patient also experienced dysgeusia while taking the medication.   Device Date was reported as 06-Jun-2022  Company comment This is a spontaneous case reported by a Health care professional, concerning a 27-year-old female patient with no relevant medical history reported, who experienced the non-serious, unexpected AESI event of COVID-19, which occurred unknown days after receiving the 3 dose of mRNA-1273 vaccine in the covid 19 vaccination series. Patient received the 2 primary doses with Moderna vaccine at an interval of about 28 days, with the last dose given about 9 months prior to the 3 dose. Concurrent medical conditions included asthma. It was reported that the patient received Paxlovid for 6 days from 26 May to 31 May 2022, for covid 19. The outcome of this event is unknown. The ongoing Covid 19 pandemia is a confounder. It was reported that COVID rebound occurred 2 days after finishing Paxlovid, on 03-Jun-2022 which was not recovered. Patient also experienced dysgeusia while taking the medication. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report. Event seriousness assessed per medical judgement.; Sender's Comments: This is a spontaneous case reported by a Health care professional, concerning a 27-year-old female patient with no relevant medical history reported, who experienced the non-serious, unexpected AESI event of COVID-19, which occurred unknown days after receiving the 3 dose of mRNA-1273 vaccine in the covid 19 vaccination series. Patient received the 2 primary doses with Moderna vaccine at an interval of about 28 days, with the last dose given about 9 months prior to the 3 dose. Concurrent medical conditions included asthma. It was reported that the patient received Paxlovid for 6 days from 26 May to 31 May 2022, for covid 19. The outcome of this event is unknown. The ongoing Covid 19 pandemia is a confounder. It was reported that COVID rebound occurred 2 days after finishing Paxlovid, on 03-Jun-2022 which was not recovered. Patient also experienced dysgeusia while taking the medication. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report. Event seriousness assessed per medical judgement.